Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raltegravir + optimized background therapy
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Raltegravir + optimized background therapy is a combination regimen used for the treatment of HIV-1 infection, particularly in adults with triple-class resistance or treatment-experienced patients. **Raltegravir** is a first-in-class HIV-1 integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome, a critical step in HIV replication. Optimized background therapy (OBT) refers to a combination of other antiretroviral agents selected based on the patient's resistance profile and treatment history, aiming to maximize virological suppression. The combination provides significantly better viral suppression and immunological recovery compared to OBT alone in patients with limited treatment options[1][2][3][5].
- Other names
- raltegravir + OBTraltegravir plus optimized background therapy
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on raltegravir + optimized background therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raltegravir + optimized background therapy.